Trombo ACC - instructions for use, analogs, reviews and release forms (tablets 50 mg and 100 mg) of the drug for the treatment of angina and the prevention of strokes and heart attacks in adults, children and pregnancy. Interaction with alcohol

In this article, you can read the instructions for using the drug Trombo ACC. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Trombo ACC in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Trombo ACC in the presence of existing structural analogues.Use for the treatment of angina and the prevention of strokes and heart attacks in adults, children, as well as during pregnancy and lactation. Composition and interaction of the drug with alcohol.

Trombo ACC non-steroidal anti-inflammatory drug (NSAID). The mechanism of action of Acetylsalicylic acid (ASA) is irreversible inhibition of cyclooxygenase, which blocks the synthesis of thromboxane A2 and inhibits platelet aggregation. It is believed that there are other mechanisms for suppressing platelet aggregation, which expands the area of ​​its use in various vascular diseases.

It also has an anti-inflammatory, analgesic and antipyretic effect.

Composition

Acetylsalicylic acid + auxiliary substances.

Pharmacokinetics

After taking the drug inside, acetylsalicylic acid is absorbed from the upper part of the small intestine. Acetylsalicylic acid undergoes partial metabolism in the liver with the formation of less active metabolites. It is excreted by the kidneys both in unchanged form and in the form of metabolites.

Indications

• prevention of acute myocardial infarction in the presence of risk factors (such as diabetes, hyperlipidemia,Arterial hypertension, obesity, smoking, old age);
• secondary prevention of myocardial infarction;
• unstable angina;
• prevention of stroke (including in patients with transient disorders of cerebral circulation);
• prophylaxis of transient disorders of cerebral circulation;
• prevention of thromboembolism after surgery and invasive vascular interventions (such as coronary artery bypass grafting, carotid endarterectomy, arteriovenous shunting, carotid angioplasty);
• prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (for example, with prolonged immobilization as a result of serious surgical intervention).

Forms of release

The tablets covered with a cover, soluble in an intestine of 50 mg and 100 mg.

Instructions for use and dosage

Tablets should be taken orally, without chewing, before eating, with a small amount of liquid.

Assign inside 50 -100 mg once a day.

Trombo ACC is designed for long-term use. The duration of therapy is determined individually.

Side effect

• hives;
• angioedema;
• anaphylactic reactions;
• nausea, vomiting;
• heartburn;
• abdominal pain;
• ulcers of the mucous membrane of the stomach and duodenum (including perforating);
• bronchospasm;
• anemia (rarely);
• increased bleeding;
• dizziness;
• noise in ears.

Contraindications

• erosive and ulcerative lesions of the gastrointestinal tract, gastrointestinal bleeding;
• "Aspirin" asthma (bronchial asthma induced by the intake of salicylates and NSAIDs);
• "Aspirin triad" (combination of bronchial asthma, recurrent nasal polyposis and paranasal sinuses and intolerance to acetylsalicylic acid);
• hemorrhagic diathesis;
• combined use with methotrexate in a dose of 15 mg or more per week;
• 1 and 3 trimesters of pregnancy;
• lactation (breastfeeding);
• children and adolescents under 18;
• hypersensitivity to acetylsalicylic acid, to auxiliary substances of the drug and other NSAIDs.

Application in pregnancy and lactation

The use of large doses of salicylates in the first 3 months of pregnancy is associated with an increased frequency of fetal development defects (split sky, heart defects). In the 2nd trimester of pregnancy, salicylates can be prescribed only with strict risk and benefit evaluation. The appointment of ASA in the last trimester is contraindicated.

Salicylates and their metabolites penetrate into breast milk in small doses. Long-term use of salicylates is the reason for stopping breastfeeding. The accidental intake of salicylates during lactation is not accompanied by the development of adverse reactions in the child and does not require the cessation of breastfeeding.

special instructions

Trombo ACC can provoke bronchoconstriction, as well as cause seizures of bronchial asthma and other reactions of hypersensitivity. Risk factors are the presence of bronchial asthma in history, hay fever, nasal polyposis, chronic respiratory diseases, as well as allergic reactions to other drugs (pruritus, urticaria).

Acetylsalicylic acid can cause bleeding of varying severity during and after surgical interventions.

The combination of Trombo ACC with anticoagulants, thrombolytic agents, antiplatelet agents is accompanied by an increased risk of bleeding.

Acetylsalicylic acid in low doses can provoke the development of gout in predisposed individuals who have decreased urinary acid excretion.

The combination of Trombo ACC and Methotrexate is accompanied by an increased incidence of side effects from the hematopoiesis system.

High doses of ASA have a hypoglycemic effect, which must be taken into account when prescribing it to patients with diabetes mellitus receiving hypoglycemic drugs.

When combined with glucocorticosteroids (GCS), it should be remembered that during treatment, the level of salicylates in the blood is lowered, and after overtreatment of SCS, an overdose of salicylates is possible.

It is not recommended to combine ASA with ibuprofen, as the latter worsens the beneficial effect of ASA on life expectancy.

When Trombo ACC is combined with alcohol, the risk of damage to the gastrointestinal mucosa and prolongation of bleeding time is increased.

Drug Interactions

With simultaneous use of Thrombot ACC enhances the effect of the following drugs:

• methotrexate by reducing renal clearance and displacing it from the bond with proteins;
• heparin and indirect anticoagulants due to impaired platelet function and the displacement of indirect anticoagulants from the connection with proteins;
• thrombolytic and antiplatelet agents (ticlopidine);
• digoxin due to a decrease in its renal excretion;
• hypoglycemic agents (insulin and sulfonylurea derivatives) due to hypoglycemic properties of ASA itself at high doses and displacement of sulfonylurea derivatives from bonds with proteins;
• valproic acid by displacing it from its bonds with proteins.

Additive effect is observed with the simultaneous administration of ASA with ethanol (alcohol).

Trombo ACC weakens the effect of uricosuric agents (benzbromarone) due to competitive tubular elimination of uric acid.

With simultaneous application of GCS, the salicylates are increased and their effect is weakened.

Analogues of the drug Trombo ACC

Structural analogs for the active substance:

• Anopyrine;
• ASA cardio;
• Aspicor;
• Aspen;
• Aspinate 300;
• Aspen Cardio;
• Aspirin;
• Aspirin Cardio;
• Acercar;
• Acentene;
• Acetylsalicylic acid;
• Acetylsalicylic acid Cardio;
• Acylpyrine;
• Acsbyrin;
• Bufferin;
• Zorex Morning;
• Cardi ASK;
• Collorite;
• Myristin;
• Plolidol 100;
• Plolidol 300;
• Taspir;
• Thrombogard 100;
• Thrombopol;
• Walsh Asalgin;
• Upsarin of the UPSA;
• Hack el-Payne.

Similar medicines:

Other medicines: